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Background: Targeted radionuclide therapy with high-energy beta-emitters is generally considered suboptimal to
cure small tumours (<300 mg). Tumour targeting of the CCK2 receptor-binding minigastrin analogue PP-F11 was
determined in a tumour-bearing mouse model at increasing peptide amounts. The optimal therapy was analysed
for PP-F11 labelled with 90Y, 177Lu or 213Bi, accounting for the radionuclide specific activities (SAs), the tumour
absorbed doses and tumour (radio) biology.
Methods: Tumour uptake of 111In-PP-F11 was determined in nude mice bearing CCK2 receptor-transfected A431
xenografts at 1 and 4 h post-injection for escalating peptide masses of 0.03 to 15 nmol/mouse. The absorbed
tumour dose was estimated, assuming comparable biodistributions of the 90Y, 177Lu or 213Bi radiolabelled peptides.
The linear-quadratic (LQ) model was used to calculate the tumour control probabilities (TCP) as a function of
tumour mass and growth.
Results: Practically achievable maximum SAs for PP-F11 labelled with 90Y and 177Lu were 400 MBq 90Y/nmol and
120 MBq177Lu/nmol. Both the large elution volume from the 220 MBq 225Ac generator used and reaction kinetics
diminished the maximum achieved 213Bi SA in practice: 40 MBq 213Bi/nmol. Tumour uptakes decreased rapidly
with increasing peptide amounts, following a logarithmic curve with ED50 = 0.5 nmol. At 0.03 nmol peptide, the
(300 mg) tumour dose was 9 Gy after 12 MBq 90Y-PP-F11, and for 111In and 177Lu, this was 1 Gy. A curative dose of
60 Gy could be achieved with a single administration of 111 MBq 90Y labelled to 0.28 nmol PP-F11 or with 4 × 17
MBq 213Bi (0.41 nmol) when its α-radiation relative biological effectiveness (RBE) was assumed to be 3.4. Repeated
dosing is preferable to avoid complete tumour receptor saturation. Tumours larger than 200 mg are curable with
90Y-PP-F11; the other radionuclides perform better in smaller tumours. Furthermore, 177Lu is not optimal for curing
fast-growing tumours.
Conclusions: Receptor saturation, specific radiopharmaceutical activities and absorbed doses in the tumour
together favour therapy with the CCK2 receptor-binding peptide PP-F11 labelled with 90Y, despite its longer
β-particle range in tissue, certainly for tumours larger than 300 mg. The predicted TCPs are of theoretical nature
and need to be compared with the outcome of targeted radionuclide experiments.
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PP-F11, a minigastrin analogue, was identified to be
one of the most promising cholecystokinin 2 (CCK2)
receptor-binding peptides to target medullary thyroid
cancer (MTC) and small cell lung cancer lesions in a
comparative search by the EU COST Action BM0607
[1]. Low retention in the kidneys by PP-F11 could be
achieved by replacement of the gastrin pentaglutamic
acid sequence in minigastrins with five D-glutamic acid
residues. Indeed in nude mice, 111In-PP-F11 showed low
retention in the kidneys in combination with a high uptake
in A431 xenografts transfected with the CCK2 receptor in
comparison with other minigastrin analogues. The tumour
and physiological organ uptake was measured at 1 and 4 h
after injection of 370 kBq/0.03 nmol 111In-labelled PP-F11.
Moreover, in vitro cell uptake experiments showed a
high affinity of PP-F11 for the CCK2 receptor and a high
internalisation rate into CCK2 receptor-transfected A431
cells [2]. The next step towards clinical application of
peptide receptor radionuclide therapy (PRRT) using
this compound is a PRRT study in mice.
Preclinical PRRT studies are typically being performed in
mice with tumours bearing an initial size of 8 to 9 mm in
diameter, which corresponds to a spherical volume of 270
to 380 mm3, but due to different growth patterns, tumours
in different animals may show large variation in size.
Low-energy beta-emitting radionuclides, such as 177Lu
and 131I, are considered favourable to maximise the
absorbed dose in tumours of this small size. For pragmatic
reasons, the choice for a therapeutic radionuclide is often
between the beta-emitters 90Y and 177Lu, as both are readily
available. The latter choice (177Lu) seems to be optimal, as
the mean beta-energy of 0.133 MeV yields a high probabil-
ity of cure in the 1- to 3-mm (0.5 to 14 mm3) size range
[3]. The high-energy beta-emitter 90Y (0.933 MeV) shows
optimal tumour control in the 28- to 42-mm range.
Neither 213Bi nor any other α-emitter was evaluated in the
paper by O'Donoghue et al., but with the availability
of 225Ac generators [4] the short-range emitter 213Bi has
become a very interesting radionuclide for PRRT as well.
The theoretical prediction of [3] was confirmed in
preclinical studies of somatostatin receptor-mediated
PRRT comparing the therapeutic effects of 177Lu-DOTA,
Tyr3-octreotate (DOTAtate) and 90Y-DOTA,Tyr3-octreotide
(DOTAtoc) in large and small tumours implanted in
rats [5,6]. With 90Y, the ideal tumour size for cure
was found to be 3 to 9 cm2 (length × width, product
of the two largest perpendicular diameters), which
corresponds to spherical tumours with diameters between
20 and 34 mm and masses between 4 and 20 g. The
absorbed dose to these tumours was between 48 and
60 Gy. With 177Lu, a more favourable response rate was
found in rats bearing smaller tumours (size <1 cm or
mass <0.5 g) compared with those bearing larger tumourmasses. The absorbed dose to these small tumours was
about 58 Gy.
We reasoned for the PRRT study that the ideal
β-emitting radionuclide for labelling PP-F11 should be
selected taking into account not only the absorbed
radiation dose, but also the relation between the uptake
kinetics in various sizes of tumours and the peptide
amount to be injected. The specific activity achievable for
each radionuclide dictates the peptide amount to be
injected for a tumour radiation dose of 60 Gy; tumour
cure is not always possible with the same peptide amount
of 0.03 nmol (corresponding to 0.1 μg) as was used
in the biodistribution study. Especially, neutron capture
reactor-produced radionuclides show a limitation in the
maximum achievable specific activity [7]. The specific
activity of the peptide should be optimized to achieve
the highest possible absorbed dose to the tumour taking
both the peptide mass with maximum receptor-mediated
uptake and the maximum achievable specific activity into
account. It is well known that unlabelled peptide will
compete with the labelled peptide for the limited
number of receptors and thereby reduce the uptake
in target tissue [8-11].
Estimation of the optimal therapy setting has been
performed in this study for preclinical testing of PP-F11,
assumed to be labelled with either 90Y, 177Lu or 213Bi.
The absorbed dose in small tumours was determined,
assuming the same biodistribution profile for all radiola-
belled analogues and taking the influence of peptide amount
on its pharmacokinetics into account as well as the radiation
transport of the emitted spectra. The aim of this study was
to determine which radionuclide is capable of reaching
tumour-sterilizing absorbed radiation doses to the tumour
of at least 60 Gy, as such a dose is expected to lead to a high
probability of tumour cure over a wide range of tumour
sizes according to the linear-quadratic (LQ) model (from 1
to 500 mm3) [3,6]. For this purpose, the most important
parameters influencing the dose-effect relation for curing
tumours have to be determined. In this study, only the
mean absorbed dose to the tumour was taken into account,
without correction for possible microdosimetry induced
enhancements of the absorbed dose effects by high linear
energy transfer (LET) spectra and/or bystander effects.
Methods
Peptide synthesis
The synthesis of the peptide PP-F11 has been described
before by Kolenc-Peitl et al. [1,12]. In summary, PP-F11
was synthesized using standard Fmoc-based solid-phase
peptide synthesis and conjugated with 1,4,7,10-tetraaza-
cyclododecane-1,4,7,10-tetraacetic acid (DOTA), using
one of the carboxylic groups of DOTA. The peptide struc-
ture was confirmed by mass spectrometry and NMR. The
amino acid sequence of PP-F11 is DOTA-DGlu-DGlu-
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NH2, and its molecular weight is 2,049 g/mol.
Radiolabelling
DOTA-conjugated peptides were radiolabelled with
111In by incubation with 111InCl3 (Covidien, Petten,
The Netherlands) in 0.25 M ammonium acetate buffer,
pH 5.0 under strict metal-free conditions. To reduce
oxidation of the peptides during radiolabelling, 100 μg
(10 μl) selenomethionine was added. The labelling
mixture was incubated for 30 min at 95°C. After incuba-
tion, 50 mM EDTA was added to a final concentration of
5 mM. Radiochemical purity and the presence of oxidized
peptide were checked on an HPLC system (1200 series
LC system; Agilent Technologies, Palo Alto, CA, USA)
equipped with an Alltima RP-C18 column (5 μm, 4.6 ×
250 mm; Alltech, Deerfield, IL, USA) and an in-line NaI
radiodetector (Raytest, Straubenhardt, Germany). A gra-
dient from 0.1% trifluoroacetic acid in water to 0.1% tri-
fluoroacetic acid in acetonitrile was used. The maximum
specific activity of the peptide was 11 GBq/μmol.
Biodistribution studies
Biodistribution and tumour targeting of the 111In-labelled
PP-F11 were studied in female athymic BALB/c mice with
subcutaneous tumours induced by inoculation of A431
cells. Mice were inoculated with 2 × 106 A431-CCK2R
cells (0.2 ml) in the left flank and with A431 mock-
transfected cells in the right flank. After approximately 10
days, when the tumours had reached a weight of approxi-
mately 100 to 200 mg, the mice were randomly divided
into groups of five mice. The mice were injected intraven-
ously with 370 kBq (0.03 nmol) of 111In-labelled peptide
via the lateral tail vein. In an additional experiment, six
groups of mice were injected with 370 kBq/0.05 nmol
111In-PP-F11 supplemented with an increasing amount
(range: 3, 10, 30, 100, and 300 times) of molar excess of
the unlabelled PP-F11 to determine the receptor satur-
ation effect as well as the non-receptor specific uptake in
CCK2 receptor-expressing tissues. Mice were killed by
CO2 asphyxiation at 1 and 4 h after administration in the
biodistribution study and after 2 h in the receptor satur-
ation study. A blood sample was drawn, and organs of
interest and the tumour were dissected, weighed and
counted in a gamma counter. The animal experiments
were approved by the local animal welfare committee and
performed according to national regulations.
Dosimetry
Tumour absorbed dose rate S-factors
Absorbed fractions of energy emitted from 90Y, 111In,
177Lu, 213Bi and its daughters were determined in a
spherical geometry using the Monte Carlo code MCNP5
(version 1.4 [13]). The mean absorbed energies werecalculated for spherical tumours of 1, 10, 100, 200, 300
and 500 mg containing ICRU-44 tissue [14] assuming an
average tissue mass density of 1 g/ml. The emission spec-
tra were taken from the Medical Internal Radiation Dose
(MIRD) radionuclide data and decay schemes book [15].
The main characteristics of the emissions by 90Y, 111In,
177Lu, 213Bi and its daughters 213Po, 209Pb and 209Tl are
listed in Table 1. Electrons and photons with an energy
below 1 keV were assumed to be absorbed at the site of
emission. The total energy emitted by electrons below 1
keV in the spectra from 111In and 177Lu is added to the
absorbed energy by the higher energy electrons. The de-
fault settings for electron and photon physics within
MCNP were used, with the exception of the electron en-
ergy straggling logic, where the option ‘DBCN 17J 2’ was
used to be independent of pre-set energy boundaries
[16,17]. For each component in the emission spectra, 10
million histories were calculated to keep the statistical
variance below 5%.
The absorbed energy distribution was determined in
each spherical tumour by using 25 equal-volume concen-
tric spherical shells within the source volume and 25
equal-volume spherical shells around the tumour extend-
ing to a radial distance of 1 cm as a consistency check of
the electron transport model used. Absorbed dose rate per
unit activity S-factors was calculated according to the equa-
tion: S ¼ k
X
i
yiEiϕi
m ; where k is a conversion factor to
dose, ϕi is the absorbed fraction of emitted energy Ei
that is emitted with yield yi, and m is the mass of the
spherical shell part. The dose to the tumour is calcu-
lated according to the MIRD scheme by the product of
the cumulated activity Ã and the absorbed dose S-fac-
tor D = Ã × S = A0 × ã × S, where A0 is the administered
activity and ã is the time-integrated activity coefficient
(TIAC; formerly indicated by residence time τ) of the
radioactivity in the tumour [18].Influence of peptide kinetics and receptor saturation on
dosimetry
The cumulated activity in the tumour Ã is based on the
111In-PP-F11 biodistribution data at 1 and 4 h for a pep-
tide mass of 0.03 nmol (0.1 μg) (Figure 1A) [5]. In mice
with s.c. CCK2 receptor-expressing A431 tumours, the
radiolabelled PP-F11 showed a high tumour uptake and
retention (9.7 ± 1.8 and 6.3 ± 2.8%ID/g, 1 and 4 h p.i.),
which was among the highest of the 12 CCK2 analogues
considered [1]. Based on the two time points, two possible
biodistribution patterns were applied to evaluate the con-
sequence of different kinetic profiles. The first approach
was a mono-exponential curve with a biological clearance
half-life of 4.9 ± 2.3 h (Figure 1B). For the second ap-
proach, an additional slower clearance compartment was
Table 1 Emission spectra and decay half-lives of 90Y, 111In, 177Lu and 213Bi and its daughters
Radionuclide Decay T1/2 Radiation Yield (/decay) Eav. (MeV) Emax (MeV)
90Y 64.1 h β− 1 0.9329 2.2801
111In 67.3 h γ 0.906 0.1713
γ 0.941 0.2454
Auger e− <1 keV 6.26 0.000159
Electrons >1 keV 1.33 0.0255
X-rays <1 keV 8.60 0.000017
X-rays >1 keV 0.901 0.0220
177Lu 159.5 h β− 1 0.1333 0.4978
γ 0.064 0.1129
γ 0.11 0.2084
Auger e− <1 keV 0.819 0.000138
Electrons >1 keV 0.452 0.0322
213Bi 45.59 min α 0.00155 5.55187
α 0.01935 5.86959
β− 0.9791 0.4339 1.4220
γ 0.261 0.44046
Auger e− <1 keV 0.474 0.000113
Electrons >1 keV 0.152 0.1261
213Po 4.2 μs α 1 8.38
209Pb 3.253 h β- 1 0.1974 0.6444
209Tl 2.161 min γ 0.998 1.57
γ 0.969 0.465
γ 0.843 0.117
Auger e− <1 keV 2.64 0.000108
Electrons >1 keV 0.830 0.0384
Energies are indicated for the beta ray (mean and maximum), Auger electrons, low-energy electrons and X-ray spectra. Below the cut-off value of 1 keV, all energy
is assumed to be absorbed at the site of emission. Only gamma rays with an emission yield of more than 0.01/decay are indicated.
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median curve between the single exponential and the
situation with just physical decay after 4 h, indicated in
Figure 1C. As not only the clearance kinetics, but also
the uptake kinetics will influence the cumulated activity,
especially for the shortest half-life radionuclide 213Bi
(Figure 1B), additionally the effect of both slow and fast
uptake kinetics was considered.
The in vivo behaviour of PP-F11 labelled with 90Y,
177Lu or 213Bi was assumed to be equivalent to that of
111In-labelled PP-F11.
The tumour uptake concentration data ([B]) as a
function of peptide mass (Mp) was fitted to the sigmoid-
shaped one-site competition curve:
B Mp
   ¼ Bunsp þ Bspec 
1þ MpED50
; ð1Þ
where [Bunsp] is the unspecific-bound concentration
asymptote at high peptide mass, [Bspec] is the receptor-bound concentration, and ED50 is the peptide mass that
lowers the tumour concentration by 50%. This curve
gives an indication of the limited number of receptors
available.
Activity for 60-Gy tumour dose
The amount of activity needed with each radionuclide to
obtain a radiation dose of 60 Gy in a 300-mg tumour is
derived for the dosimetry according to the 0.03 nmol
peptide mass biodistribution. The dosimetry is adjusted
according to the peptide mass needed to label the pep-
tide at a practically achievable specific activity using the
logarithmic receptor saturation function. Traditionally,
the activity A0(Mp) needed to obtain an absorbed dose D
in a tumour with mass m and using the biodistribution
for a peptide mass of Mp = 0.03 nmol is obtained by:
A0 0:03ð Þ ¼ DeamS m←mð Þ: ð2Þ
Figure 1 Biodistribution and kinetic profile. (A) Biodistribution of 0.03 nmol 111In-labelled PP-F11 in nude mice with CCK2R-transfected A431 tumour
xenografts at 1 and at 4 h (reproduced from [1]). (B) Kinetic profile of radioactivity uptake in the CCK2 receptor-positive tumour xenograft with three
options that are considered for the uptake phase: single-exponential, fast uptake with T1/2 of 2.7 min and slow uptake with T1/2 of 17 min. (C) Variance in
kinetic profile of the radioactivity clearance from the tumour: the solid blue curve shows the single exponential with T1/2 of 4.9 h, the middle dashed red curve
shows the double exponential with final clearance T1/2 of 150 h and the blue dotted curves show the 95% confidence interval for the tumour clearance.
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mass Mp changes for the maximum (achievable) specific
activity Asp at both sides of the equation:
A0 Mp
  ¼ Mp  Asp ¼ B 0:03ð Þ½ D
B Mp
  eamS m←mð Þ: ð3Þ
This equation can be solved to obtain the amount of
peptide mass Mp needed with specific activity Asp that
will deliver a dose D in a tumour with mass m. Not only
the absorbed dose but also the amount of peptide, the
specific activity used and the total number of receptorbinding sites available are of importance. It is assumed
the shape of the kinetics does not change with peptide
mass, just the uptake value itself. The maximum and
practically achievable specific activities for labelling pep-
tides with 111In, 90Y and 177Lu are indicated in Table 2,
as obtained from Breeman et al. [7]. Maximum specific
activity is reached when 1 nmol of DOTA incorporates 1
nmol of radionuclide. In practice, the specific activity is
severely hampered by the reaction kinetics and challenged
uptake by contaminants in the radionuclide solution, either
from target material or from radioactive decay products.
The highest practically achievable specific activity is
Table 2 Production methods and specific activities (SA) of 90Y, 111In, 177Lu and 213Bi, both per nmol PP-F11 with
2,049 g/mol
90Y 111In 177Lu 213Bi
Production route Elution from 90Sr generator Cyclotron 112Cd(p,2n)111In Reactor 176Lu(n,γ)177Lu Elution from 225Ac generator
Maximum SA (GBq/nmol) 1.8 1.7 0.73 153
Practical SA (MBq/nmol) 400 800 120 40
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higher specific activity (SA) than 177Lu. The administered
amount of peptide per injection was maximised at 0.5
nmol (1.02 μg) to stay within practically feasible limits in
both volume and radioactivity. The practical limit in spe-
cific activity of 213Bi-labelled peptides was obtained at our
institute with a 220 MBq 225Ac generator.
The practical achievable SA of 213Bi with peptide is
much lower than after labelling with 90Y, 111In or 177Lu,
due to the at least twice higher reaction volume with
213Bi. The elution volume of the generator is fixed at
approximately 600 μL, dependent on the generator bed
volume in the preclinical setting using a 220 MBq 225Ac
generator. Generators containing higher amount of 225Ac
activity have larger bed volumes and higher elution vol-
umes [4,19]. High labelling volume or low concentration
of the labelled compounds results in poor reaction kinetics
of the labelling, which can be solved by increasing the
temperature or taking a longer reaction time. However, at
a very high temperature, denaturation of biological mate-
rials might occur, and in the case of 213Bi, a longer reac-
tion time will result in decay of activity. By reducing the
elution volume and reaction time of 213Bi labelling, a
higher SA can be achieved. Presently, the time between
elution and injection in the animal is in the order of 30
min, by which already 36% of the initial 213Bi radioactivity
has decayed.
Tumour control probability model
The suitability of the radionuclide for treating a tumour
xenograft is investigated by constraining the tumour
control probability (TCP) to at least 90% according to
[3,20,21]:
TCP ¼ exp −NclonogensS Dð Þ
 
; ð4Þ
with S Dð Þ ¼ exp −αD 1þ G
α
β
  D
N
0@ 1A0@ 1A;with G ¼
Tμ
Tμ þ T eff
Tμ
Tμ þ T 1 T 1A1ð Þ
2 þ 2TμT 1T 2 TμT 1 þ TμT

Tμ þ T 1
 
Tμ þ T2
 ð
T 1A1 þ T 2Að
8>>><>>>:The survival S of clonogenic cells as a function of dose
D in the tumour is described by the linear-quadratic
model. The dose per fraction D/N is used in the quad-
ratic term to allow correction for fractionation of the
therapy. The dose prolongation or Lea-Catcheside factor
G is used to adjust the quadratic part of the LQ model
for radionuclide-induced dose rates. During the expos-
ure with effective half-life Teff, sub-lethal damage is
being repaired according to an exponential function with
repair half-life Tμ. The single-exponential clearance with
effective half-life Teff is indicated in Equation 4a for G.
Equation 4b is for a bi-exponential clearance curve with
effective half-lives T1 and T2 and amplitudes A1 and A2.
The second expression for G (4b) can be modified to
take the uptake kinetics into account, with A2 = −A1 and
A tð Þ ¼ A1 e−λ1t−e−λ2t
 
; which leads to
G ¼ Tμ T 1Tμ þ T 2Tμ þ T 1T2
 
T1 þ T 2ð Þ T1 þ Tμ
 
T 2 þ Tμ
  : ð5Þ
In this work, the clonogenic cell density is assumed to
be 10% of the total cell density of 109/g. The following LQ
model parameters were considered: α = 0.27 Gy−1, α/β = 6
Gy and Tμ = 0.5 h (squamous cells, see [22]). The repair
half-life of 0.5 h is in the lower range for tumour sub-
lethal repair half-lives [23].
Effect of tumour growth on TCP
Correction of TCP for tumour growth with doubling
time TD during the dose accumulation was made by in-
cluding the tumour growth in the LQ model equation
for cell survival:
S D;Tð Þ ¼ exp −αD Tð Þ 1þ G
α=β
 D Tð Þ
N
 !
þ γT
 !
; ð6Þ
where γ = ln(2)/TD and T is the irradiation time. Over-
all, the TCP is adjusted by taking the power with eγTirr4að Þ
2 þ T 1T2

T 1 þ T2Þ
A1A2 þ TμTμ þ T 2
T2A2ð Þ2
2Þ2
4bð Þ
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time Tirr when the slope, or derivative, of the cell survival
curve remains positive, as the radiation effect outweighs
the tumour growth [24]. The tumour doubling time for
the A431-CCK2R cells was determined to be 4 days [25].
Only the absorbed dose delivered to the tumour before
the irradiation time Tirr has passed can be considered
effective in cell kill. Therefore, both the absorbed dose
and the TCP were corrected for the efficacious dose Deff
and the tumour growth during the irradiation time, with:
Deff ¼ S m←mð Þ
Z T irr
T0
A tð Þdt: ð7Þ
In the case that it was impossible to give curative
doses with the radionuclide in one administration, a
treatment interval of 24 h between subsequent injections
was assumed with unaltered growth in the treatment
gap in between.
Results
Biodistribution studies
In mice with s.c. CCK2 receptor-expressing A431 tu-
mours, the radiolabelled PP-F11 showed a high tumour
uptake and retention (9.7 ± 1.8 and 6.3 ± 2.8%ID/g, 1 and
4 h p.i.) [1]. The mono-exponential curve with a biological
clearance half-life of 4.9 ± 2.3 h (Figure 1B) leads to higher
cumulative activities for the shorter half-life radionuclides
such as 90Y and 213Bi in comparison to 177Lu. An add-
itional clearance compartment was assumed with a
clearance half-life of 150 h, being a median curve
between the single exponential and the situation with
just physical decay after 4 h, indicated in Figure 1C.
Not only the clearance kinetics but also the uptake kinet-
ics will influence the cumulated activity, especially for the
shortest half-life radionuclide 213Bi (Figure 1B). The effect
of both slow and fast uptake on the cumulated activity
was considered.
The effect of increasing PP-F11 peptide mass on the
uptake of the radiolabelled peptide in the tumour and
the normal tissues is shown in Figure 2A. In the CCK2R-
expressing tumour and stomach, the radioactivity uptake
decreased with increasing peptide dose injected. This
decrease was fitted with one-site dissociation curves
(Equation 1) shown in Figures 2B,C.
Dosimetry
Absorbed dose in tumours
Absorbed dose rates per MBq activity (S-values) were
calculated for 90Y, 111In, 177Lu, 213Bi, 213Po, 209Pb and
209Tl in small spherical tumours and are indicated in
Table 3. For 111In and 177Lu, almost the complete emitted
internal conversion electron and beta-energy are absorbed
in the largest sphere, whereas for 90Y, only 61% of theemitted energy is absorbed. In the 1-mg sphere the energy
absorption ϕ = 10% for 90Y and ϕ = 80% and 69% for 111In
and 177Lu, respectively. The absorbed energy fractions by
the α-particles from 213Bi and 213Po are more than 95%
in the smallest sphere and reach 100% in the 100-mg
spheres.
The TIACs per gram of tumour, listed in Table 4, were
obtained by integration of the time-activity curves of
Figure 1B,C. Non-instantaneous uptake kinetics has the
most influence on the TIAC for 213Bi and 213Po, e.g. 19%
difference between the single exponential and slow uptake
values. Slower uptake kinetics will influence the other
radionuclides by maximally 6% in single-exponential
clearance and by less than 3% for the double-exponential
clearance pattern, assuming linear scaling of the uptake
with tumour mass delivers the mean absorbed tumour
doses per administered activity as listed in Table 5. These
absorbed doses, however, are only valid for 0.03 nmol
PP-F11. When this amount of peptide is used, the max-
imum absorbed doses with the β-emitting radionuclides
for both types of clearance rates are obtained with 90Y,
e.g. for an injected activity of 12 MBq 90Y which can be
labelled to 0.03 nmol PP-F11, the dose to a 300-mg
tumour is 3 to 9 Gy for the single and the double expo-
nential clearance rate, respectively. The absorbed doses
using the other radionuclides are much lower, around 1
Gy. Therefore, multiple injections with more peptide
amounts are needed to achieve 60 Gy.
Effect of peptide mass
Higher amounts of peptide are needed to guide higher
amounts of radioactivity and higher absorbed doses to
the tumour. However, increasing the amount of peptide
will at the same time reduce the tumour TIAC, according
to the saturation curve shown in Figure 2. We postulated
that the kinetics of the peptide clearance were not influ-
enced by the saturation effect, but only the final uptake at
each time-point, expressed as %IA/g.
Taking the single-exponential clearance rate into ac-
count, an absorbed dose of 60 Gy in a 300-mg tumour
can only be achieved by administering 5 nmol of PP-F11
peptide labelled with 2 GBq of 90Y or with 123 MBq 213Bi
labelled to 0.081 nmol of PP-F11. In Table 6, an overview
is listed of activities and peptide mass needed to reach an
absorbed dose of 60 Gy in a 300-mg tumour for the
double-exponential clearance pattern, either by single
or multiple (N) injections with 90Y, 111In, 177Lu and
213Bi labelled to PP-F11, together with the absorbed
doses in other tumour sizes, varying from 1 to 500 mg.
The TCPs for absorbed doses of 60 Gy in a 300-mg
tumour are 77% for 90Y, 74% for 111In, and 48% for 177Lu
when given in one fraction, according to Equation 4. With
fractionated therapy, the TCP drops to 21% (90Y), 16%
(111In) and 12% (177Lu), despite the same dose of 60 Gy.
Figure 2 Biodistribution and fit of displacement curve. (A) Biodistribution of 111In-labelled PP-F11 with increasing excess unlabelled peptide
in nude mice (N = 5) with CCK2R-transfected A431 tumour xenografts at 2 h after injection, showing saturation of uptake in the CCK2R tumours
and stomach. (B) Fit of displacement radioactivity curve to the CCK2R tumour xenograft data with log(ED50) = −9.30 ± 0.19 (ED50 = 0.51 nmol
(95% CI: 0.2 to 1.2), correlation R2 = 0.80). (C) Fit of displacement curve to stomach uptake data with log(ED50) = −10.54 ± 0.38 (ED50 = 0.03 nmol
(0.005 to 0.17), R2 = 0.85). Error bars indicate standard deviations of the mean values.
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rates, either by the radionuclides' half-lives or by the
fractionation scheme. The TCP for 213Bi PP-F11 de-
pends on the relative biological effectiveness (RBE) of
its α-radiation (93% of the absorbed dose), which is not
clear yet. A RBE higher than 1.2 will already result in a
TCP of more than 90% in all tumours below 300 mg.
Previously, the RBE for cell killing by 213Bi-DOTA-
octreotate has been shown to be 3.4 [26]. If this would
also be the case for 213Bi-PP-F11, 90% TCP will already
be reached with 4 × 17 MBq (0.41 nmol).When single-exponential clearance is assumed with
consequently higher initial dose rate, the G-factor shows
a rise: 60 Gy yields higher TCPs of 99% (90Y), 32%
(111In) and 20% (177Lu) vs. double-exponential clearance
kinetics (Figure 3). The absorbed dose needed for a TCP
of 90% is 42 Gy with a single-exponential curve and
single-fraction administration. For both clearance pat-
terns, only 90Y and 213Bi are capable of delivering these
curable doses, as shown in Figure 3 for the situation
which does not take tumour growth into account, 213Bi to
the whole range and 90Y only to the larger size tumours.
Table 3 S-values for 90Y, 111In, 177Lu and 213Bi with its daughters, in spheres with masses between 1 and 500 mg
Mass (mg) Absorbed dose rate per radioactivity S-value (mGy/MBq s)
90Y 111In 177Lu 213Bi 213Po 209Pb 209Tl
1 15.4 4.66 17.0 37.6 1273 17.4 19.4
5 5.21 1.04 3.92 9.55 260 4.48 6.14
10 3.26 0.539 2.05 5.28 131 2.41 3.72
50 1.06 0.112 0.436 1.30 26.5 0.545 1.08
100 0.643 0.0576 0.222 0.695 13.3 0.281 0.643
200 0.381 0.0295 0.113 0.367 6.65 0.144 0.364
300 0.278 0.0200 0.0756 0.252 4.44 0.0971 0.258
500 0.184 0.0123 0.0457 0.156 2.67 0.0591 0.166
The radioactivity was homogeneously distributed in the tissue-like material spheres within the calculation model set up with MCNP5 v1.4 [13].
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tumour size: 76% to 81% in 1 mg with 111In and 72% to
76% in 5 mg with 177Lu. The absorbed dose needed for a
TCP of 90% in a 300-mg tumour with 177Lu is 70 Gy. The
quadratic term is determinant for the TCP for the low-
LET radiation, leading to higher TCPs for the single-
exponential clearance pattern and to TCPs of 0 when the
quadratic LQ model term β is neglected. The high
amounts of total radioactivity needed to obtain cure with
the β-emitters for the single-exponential clearance are not
practically achievable.
The dose effect by 213Bi is not influenced by the quad-
ratic term of the LQ model due to the fact that 95% of
its absorbed dose is caused by high LET α-radiation
without repairable damage. Because of the short half-life,
the uptake kinetics, however, do show a large influence
on the cure possibilities with 213Bi (Figure 2A). When
the slow uptake kinetics (T1/2 = 16 min) are applied, the
absorbed dose will be reduced by 18%, whereas for the
fast uptake (T1/2 = 7 min), only a 4.2% reduction in dose
is observed in comparison to the absorbed dose for in-
stantaneous uptake. Compensation for this possible dose
reduction can be obtained by administering either one
additional therapy cycle or 9% more radioactivity per
cycle.Table 4 Tumour time-integrated activity coefficients (TIAC)
per mass for 90Y, 111In, 177Lu and 213Bi with its daughters
Kinetics TIAC per tumour mass [in s/g]
90Y 111In 177Lu 213Bi 213Po 209Pb 209Tl
1 − Exponential 261 262 272 380 372 228 8
+ Fast uptake 258 259 269 361 353 230 8
+ Slow uptake 245 246 256 309 303 238 7
2 − Exponential 928 956 1,523 388 380 256 8
The clearance kinetics was modeled by a single-exponential (1-Exp) or by
double (2-Exp) clearance (see Figure 1B,C). The uptake kinetics in the case of
single-exponential clearance was either instantaneous (1-Exp) or according to
the fast or slow uptake curves indicated in Figure 1B. All values are for a
peptide amount of 0.03 nmol PP-F11.Influence of tumour growth rate
The tumour doubling time influences the tumour cure pos-
sibilities in therapies which need the double-exponential
clearance kinetics to reach therapeutic doses. The irradi-
ation time Tirr indicates the time until the radiation cell
kill outnumbers the tumour growth. With 111 MBq 90Y
(sufficient to cure a static 300-mg tumour), Tirr can vary
between 184 h (Tdoubling of 2 days) and 354 h (Tdoubling of
28 days). When 90Y is given in 4 × 20 MBq with 24-h
interval, Tirr ranges between 218 and 389 h. The irradi-
ation times for 5 × 359 MBq 111In are comparable to those
of 90Y: 237 and 414 h. With 6 × 47 MBq 177Lu, the tumour
growth takes over at later times: its irradiation times vary
between 317 h (Tdoubling of 2 days) and 611 h (Tdoubling of
28 days). For therapy with 213Bi, the influence of the
tumour doubling time is much less (16.8 MBq 213Bi: 6.7 h
(for Tdoubling of 2 days) and 11 h (for Tdoubling of 28 days)).
The build-up of the dose over this irradiation time is
reduced in comparison to the build-up to infinity; for
213Bi, the reduction is below 0.5% and negligible like the
maximal 5% reduction with 90Y, but with 177Lu, it is 18%
at Tdoubling of 2 days and 5% at Tdoubling of 28 days. Both
the effects by reduction in dose and tumour growth
during the irradiation have influence on the tumour
cure probabilities, as shown in Figure 4 for the double-
exponential clearance.
The reduction in tumour size as a function of time is
shown in Figure 5 during a time period of 60 days. None
of the tumours with a doubling time of more than 4 days
grow back to their original size within this time period.
The reduction in size is proportional to the radionuclide
half-life and intervals (here 24 h) between the injections.
Discussion
Based on studies with 12 CCK2 receptor-binding an-
alogues, the biodistribution of the CCK2 analogue
PP-F11 shows a very favourable uptake in CCK2
receptor-expressing tumours and relatively low renal re-
tention, which makes it potentially suitable for therapeutic
Table 5 Mean absorbed doses per administered activity for 90Y, 111In,177Lu and 213Bi (including daughters) labelled to
0.03 nmol PP-F11
Mass (mg) Absorbed dose per administered activity (mGy/MBq)
90Y 111In 177Lu 213Bi + daughters
1-Exp 2-Exp 1-Exp 2-Exp 1-Exp 2-Exp 1-Exp 2-Exp
1 40 143 12 45 46 259 492 503
5 68 242 14 50 53 299 508 519
10 85 302 14 52 56 311 514 525
50 139 493 15 54 59 332 524 536
100 168 597 15 55 60 338 527 539
200 199 708 15 57 61 343 530 542
300 217 773 16 57 62 345 532 544
500 240 853 16 59 62 348 533 545
Tumour spheres vary in mass between 1 and 500 mg. Single-exponential (1-Exp) clearance proceeds with T1/2 = 4.8 h and double-exponential (2-Exp) clearance
with T1/2 = 2.7 h (60%) and 150 h (40%).
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and hurdles for successful radionuclide therapy with
this peptide analogue in mice with s.c. CCK2 receptor-
expressing tumours. The particle range of the selected
radionuclides has an important impact on the cure
capability of the radioloabelled peptide for various sizes
of tumours [3]. Since the receptor-mediated tumour up-
take of radiolabelled PP-F11 shows a saturable relation
with peptide mass, the maximum achievable specific activ-
ity is an important parameter in this respect. Furthermore,
it has to be taken into account that the production
method of radionuclides determines the amount that can
be labelled to peptides. Therefore, the higher specific
activities reachable with 90Y and 213Bi make both ra-
dionuclides very suitable for therapy of 200- to 300-mgTable 6 Activities and peptide mass needed for an absorbed
90Y - PP-F11
N × activity (MBq) 1 × 111 4 × 20
N × peptide (nmol) 0.28 4 × 0.05
Relative uptake (%) 70 97
Tumour mass (mg) Me
1 11
5 19
10 23
50 38
100 46
200 55
300 60
500 68
Multiple (N) injections were considered; only 90Y could attain 60 Gy by a single inje
indicated. The mean absorbed doses are given for tumour spheres varying in mass
double-exponential clearance with T1/2 = 2.7 h (60%) and 150 h (40%) without tumo
effectiveness (RBE = 1).tumours, using lower peptide mass and thus higher
tumour uptake. Yttrium (90Y) is capable of controlling
larger-sized (>200 mg) tumours, whereas 213Bi is capable
of curing over the whole range of masses considered, but
most optimal in the smallest sizes.
This receptor saturation effect has been observed previ-
ously with somatostatin receptor-targeted peptides, both
in preclinical biodistribution studies [9], as in clinical use
[27,28], and has also been observed even more promin-
ently with bombesin analogues [29]. The limited number
of receptors influences the tumour uptake of the peptide
at escalating peptide doses. Pharmacokinetic compartment
modelling can be used to correct for the molar concentra-
tion and receptor binding [11]. In this study, we used
the one-site dissociation curve to describe the saturabledose of 60 Gy in a 300-mg tumour
111In - PP-F11 177Lu - PP-F11 213Bi - PP-F11
8 × 174 6 × 47 10 × 19
8 × 0.21 6 × 0.39 10 × 0.47
75 62 57
an absorbed dose to tumour (Gy)
47 45 55
52 52 57
54 54 58
56 58 59
57 59 59
59 60 60
60 60 60
61 38 60
ction. The relative uptake reduction factor by the higher peptide mass is
between 1 and 500 mg according to the mentioned activity and assuming the
ur growth. The absorbed dose for 213Bi was not corrected for its relative
Figure 3 Tumour control probability. TCP as a function of tumour mass at activities producing a TCP of 90% in a static 300-mg tumour, or an
absorbed dose of 60 Gy when lower. The clonogenic tumour cell density was 108/g and the LQ model parameters were α = 0.27 Gy−1, α/β = 6 Gy
and Tμ = 0.5 h. For the alpha-particle part of the dose by
213Bi, RBE = 3.4. (A) Single-exponential clearance kinetics and (B) double-exponential
clearance kinetics.
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uptake in humans after PRRT with 177Lu-DOTA-octreotate
has not been observed, whereas the receptor-mediated up-
take in the liver and spleen did show a decrease by the
therapeutic amount of peptide [30].
The α-emitter 213Bi shows ideal properties to cure small
lesions, with most of its absorbed dose coming from its
short half-life daughter 213Po. The RBE of 213Bi-PP-F11 is
not known, but when the effects are comparable to the
RBE found for 213Bi-DOTΑ-octreotate of 3.4 [26], its
effect is tremendous. The absorbed dose to the normal or-
gans such as the kidneys and stomach wall has not been
considered in this evaluation, as kidney protection by
blocking reuptake of the peptide can reduce the renal dose
[31,32]. For all radionuclides, radiation-induced toxicity in
normal organs will form the limiting amount of radio-
activity. Late kidney damage will occur after cumulative
doses of >27 Gy with 90Y-DOTA-octreotide [33]. Renal
uptake of the PP-F11 peptide is hardly influenced by the
injected peptide mass, contrary to the tumour uptake.
Consequently, using a higher amount of peptides to in-
crease the amount of radioactivity will lead to higher
absorbed doses to the kidneys while the tumour absorbed
doses are decreased due to receptor saturation. The
stomach wall will show radiation-induced ulceration
after 45-Gy fractionated external beam exposure [34].
For that reason, it is most probably not realistic to admin-
ister the huge amounts of radioactivity as suggested for
111In and 177Lu in the case of single-exponential clearance
(Figure 3A).
Fractionation of the therapy is necessary for the prac-
tically achievable specific activities of the radionuclides
considered. Fractionation will lead to higher cumulative
absorbed doses in tumours and has been shown to lead
to lower probability of renal toxicity in clinical application
of radionuclide therapy [35]. Fractionation of therapy with
177Lu-DOTA-octreotate in rats with CA20948 tumourshas been shown to reduce renal toxicity while maintaining
the same tumour response as for the single fraction ther-
apy [36]. This reduction in renal toxicity was also influ-
enced by the time interval between the fractions; renal
toxicity was significantly reduced for intervals of a week
or longer compared to a 1-day interval. This inter-fraction
recovery of renal damage is not fully explained by the
repair mechanism within the LQ model [37]. In clinical
practice, 177Lu-DOTA-octreotate is given in four fractions
of 7.4 GBq with a 6-week interval, also in order to allow
the bone marrow to recover [38].
The tumour growth rate has a large influence on the
cure options using the longer half-life radionuclides.
Tumours with a doubling time of less than 8 days
show >50% reduction of the TCP for treatment using
90Y or 111In, and with 177Lu, this reduction sets in at
doubling times below 14 days. Due to its short half-life,
213Bi is capable of controlling also fast-growing tumours.
This growth effect is only of concern in preclinical studies
with fast-growing tumour xenografts and hardly in the
clinical setting in which tumour doubling times most
often are longer than 14 days. Selective control of slower
growing tumour subtypes could however induce a more
aggressive type in any tumour regrowth. The concept of
TCP may be a too strict criterion for cure, as for slower
growing tumours, the regrowth may not be visible within
the typical observation period of 2 to 3 months. A lag time
without tumour growth and subsequent accelerated re-
population as observed in prolonged radiotherapy sessions
has not been modelled [39]. The effect of repopulation
after radionuclide therapy needs to be investigated further
as it will strongly influence the cure rates for fast-growing
tumours, e.g. with a lag time of 7 to 8 days, all growth
effects would diminish when the therapy is completed
within 1 week. The size of the tumour may not be com-
pletely representative for the number of viable cells within
this volume. Doomed cells can form a part of the tumour
Figure 4 Tumour control probability vs tumour mass. TCP versus tumour mass for a single 111 MBq 90Y (A), multiple administrations 4 × 20
MBq 90Y (B), 5 × 359 MBq 111In (C), 6 × 47 MBq 177Lu (D) and 4 × 16.8 MBq 213Bi (E) for tumour doubling times varying between 1 and 28 days,
and for the static tumour, as shown in Figure 3. Only bars for TCP > 0.05 are shown, except for 213Bi where the 14- and 18-day doubling time
results were almost equal to the static (without tumour growth) TCP shown with the blue bars.
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cleared or encapsulated [40].
The basis for the radiobiological considerations is
formed by the linear-quadratic model, which assumes
that the tumour cells behave as cells in culture in response
to radiation. The main LQ model parameters α and β are
determined from external beam experiments. Response to
radionuclide-induced doses is also very dependent on the
repair process of sub-lethal damage. In external beamexposure, this repair takes place immediately after the
dose given in a short time. With radionuclide-induced
exposure, the repair is induced during the dose delivery
and therefore the half-time value with which sub-lethally
damaged lesions are repaired is very critical. In this work,
this repair half-time was taken as 0.5 h, which is consid-
ered to be valid in general for tumours. Changing the
repair half-time to 1 h increases the TCP by 10% to 20%
for the beta-emitting radionuclides. Future work on
Figure 5 Models for tumour growth curves. After multiple administration of (A) 90Y, (B) 111In, (C) 177Lu or (D) 213Bi to a 300-mg tumour for
different tumour doubling times. The same amount of peptide was used as indicated in Figure 4.
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focus on the repair mechanism and the influence of kinet-
ics. The clearance kinetics is a dominant factor not only in
the absorbed dose to the tumour, but also in the TCP by
the projected dose rate. It is therefore of great importance
to determine the kinetic pattern with more detail than just
the two time points as taken in this study. Fractionation of
radionuclide therapy should be studied on the basis of the
absorbed doses given, taking the radiation sensitivity, the
repair of sub-lethal damage and recovery by repopulation
into account.
Conclusions
Receptor-mediated uptake of the CCK2 compound PP-F11
in tumours shows a steep saturation effect with increasing
amounts of peptide.
The specific activities achievable for radiolabelling
peptides limit the absorbed dose in tumours, as higher
activities go parallel with higher peptide amounts, which
might considerably reduce the tumour uptake.
Multiple injections are preferred to obtain an absorbed
tumour dose in the order of 60 Gy.
For the larger xenografts (>200 mg), 90Y is the prefera-
ble radionuclide, as its high specific activity allows the useof low peptide amounts, although it lacks the capability of
curing smaller-sized tumours.
For tumour xenografts in almost the whole size range
(<500 mg), 213Bi shows highTCPs, taking an enhancement
by increased RBE from its α-radiation into account.
The influence of the clearance kinetics is the largest
with 177Lu, whereas 213Bi is most strongly influenced by
the uptake kinetics.
Ongoing growth of the tumour during the absorbed
dose build-up reduces the TCP for longer half-life radio-
nuclides and has hardly any influence on the cure options
for 213Bi.
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